Research programme: SNA based therapeutics - Exicure

Drug Profile

Research programme: SNA based therapeutics - Exicure

Alternative Names: SNA constructs - Exicure; SNA targeting IL17RA - Exicure; SNA targeting IL4RA - Exicure; Spherical nucleic acid constructs - Exicure; XCUR17

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AuraSense Therapeutics
  • Developer Exicure
  • Class Antifibrotics; Antineoplastics; Antipsoriatics; Eye disorder therapies; Nucleic acids; Skin disorder therapies
  • Mechanism of Action Gene modulators; Immunomodulators; Immunosuppressants; Interleukin 1 beta modulators; Interleukin 17 receptor modulators; Interleukin 4 receptor modulators; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Atopic dermatitis; Brain cancer; Cancer; Fibrosis; Inflammation; Lymphoma; Psoriasis; Skin disorders; Solid tumours; Transplant rejection
  • Research Epidermolysis bullosa; Eye-Disorders; Gastrointestinal disorders; Respiration disorders

Most Recent Events

  • 09 Mar 2018 Exicure plans a phase I trial of XCUR17 for Psoriasis in Germany in early 2018
  • 05 Mar 2018 Preclinical trials in Atopic dermatitis in USA (unspecified route) (Exicure pipeline, March 2018)
  • 01 Feb 2018 Exicure receives approval from Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for conduction of a phase I trial in Psoriasis in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top